White Diamond Research says the publication Lixte Biotechnology highlighted in a press release yesterday is not new. The firm said in a report on its website: “Tthis publication wasn’t new. LIXT stated ‘that there was a publication of pre-clinical data today (3/27/24) in the online journal Cancer Discovery, showing that its lead clinical compound, LB-100, can force cancer cells to give up their cancer-causing properties in a paper entitled ‘Paradoxical activation of oncogenic signaling as a cancer treatment strategy.’…However, this exact same publication, word for word, was published on 2/7/23, over a year ago here.” Shares of Lixte are down 2% to $3.45 in late morning trading.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIXT:
- Lixte Biotechnology announces publication on LB-100 in cancer cells
- Lixte Biotechnology provides update on progress with LB-100
- LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
- Lixte Biotechnology announces presentation of LB-100
- LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
